ACM
REGN icon

Advisors Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Advisors Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$232K Buy
371
+76
+26% +$51.7K ﹤0.01% 579
2026
Q1 		$228K Buy
295
+10
+4% +$7.66K ﹤0.01% 528
2025
Q4 		$220K Buy
+285
New +$194K ﹤0.01% 540
2025
Q2 		– Sell
-921
Closed -$584K – 532
2025
Q1 		$584K Sell
921
-801
-47% -$551K 0.01% 341
2024
Q4 		$1.23M Sell
1,722
-35
-2% -$29.4K 0.02% 281
2024
Q3 		$1.85M Buy
1,757
+174
+11% +$194K 0.03% 252
2024
Q2 		$1.67M Buy
1,583
+8
+0.5% +$7.75K 0.03% 260
2024
Q1 		$1.52M Buy
1,575
+2
+0.1% +$1.9K 0.03% 263
2023
Q4 		$1.38M Buy
1,573
+1,181
+301% +$973K 0.03% 269
2023
Q3 		$323K Sell
392
-3
-0.8% -$2.36K 0.01% 348
2023
Q2 		$284K Buy
395
+14
+4% +$10.8K 0.01% 373
2023
Q1 		$313K Buy
381
+4
+1% +$3.02K 0.01% 365
2022
Q4 		$272K Sell
377
-3
-0.8% -$2.21K 0.01% 389
2022
Q3 		$282K Buy
380
+7
+2% +$4.41K 0.01% 396
2022
Q2 		$220K Sell
373
-2
-0.5% -$1.3K 0.01% 407
2022
Q1 		$262K Buy
+375
New +$237K 0.01% 386

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Advisors Capital Management's REGN Position: Q2 2026 in Review

Advisors Capital Management increased its Regeneron Pharmaceuticals (REGN) stake by 26% in Q2 2026, buying an estimated $51.7K and bringing the position to 371 shares worth $232K. The position accounts for ﹤0.01% of the portfolio, ranked #579.

Advisors Capital Management first reported a position in REGN in Q1 2022 and has held it in 16 quarters since. The position peaked at $1.85M in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Advisors Capital Management held 371 shares of Regeneron Pharmaceuticals worth $232K as of Q2 2026.
  • Advisors Capital Management bought 76 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $51.7K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Advisors Capital Management's portfolio in Q2 2026, its #579 holding.
  • Advisors Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2022 and has held it in 16 quarters since.
  • Advisors Capital Management's Regeneron Pharmaceuticals position peaked at $1.85M in Q3 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Advisors Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.